BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27150568)

  • 1. The c.657del5 variant in the NBN gene predisposes to pancreatic cancer.
    Borecka M; Zemankova P; Lhota F; Soukupova J; Kleiblova P; Vocka M; Soucek P; Ticha I; Kleibl Z; Janatova M
    Gene; 2016 Aug; 587(2):169-72. PubMed ID: 27150568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic.
    Borecka M; Zemankova P; Vocka M; Soucek P; Soukupova J; Kleiblova P; Sevcik J; Kleibl Z; Janatova M
    Cancer Genet; 2016 May; 209(5):199-204. PubMed ID: 27106063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?
    Seemanova E; Varon R; Vejvalka J; Jarolim P; Seeman P; Chrzanowska KH; Digweed M; Resnick I; Kremensky I; Saar K; Hoffmann K; Dutrannoy V; Karbasiyan M; Ghani M; Barić I; Tekin M; Kovacs P; Krawczak M; Reis A; Sperling K; Nothnagel M
    PLoS One; 2016; 11(12):e0167984. PubMed ID: 27936167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited NBN Mutations and Prostate Cancer Risk and Survival.
    Rusak B; Kluźniak W; Wokołorczykv D; Stempa K; Kashyap A; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Masojć B; Akbari MR; Narodv SA; Lubiński J; Cybulski C
    Cancer Res Treat; 2019 Jul; 51(3):1180-1187. PubMed ID: 30590007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk of heterozygotes with the NBN founder mutation.
    Seemanová E; Jarolim P; Seeman P; Varon R; Digweed M; Swift M; Sperling K
    J Natl Cancer Inst; 2007 Dec; 99(24):1875-80. PubMed ID: 18073374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic modification of breast cancer risk in women with an NBN mutation.
    Rusak B; Kluźniak W; Wokołorczyk D; Stempa K; Kashyap A; Rudnicka H; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Szwiec M; Akbari MR; Narod SA; Lubiński J; Cybulski C;
    Breast Cancer Res Treat; 2019 Nov; 178(2):427-431. PubMed ID: 31410679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic.
    Pardini B; Naccarati A; Polakova V; Smerhovsky Z; Hlavata I; Soucek P; Novotny J; Vodickova L; Tomanova V; Landi S; Vodicka P
    Mutat Res; 2009 Jun; 666(1-2):64-7. PubMed ID: 19393249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
    Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland.
    Steffen J; Varon R; Mosor M; Maneva G; Maurer M; Stumm M; Nowakowska D; Rubach M; Kosakowska E; Ruka W; Nowecki Z; Rutkowski P; Demkow T; Sadowska M; Bidziński M; Gawrychowski K; Sperling K
    Int J Cancer; 2004 Aug; 111(1):67-71. PubMed ID: 15185344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
    Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
    Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
    Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
    J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland.
    Steffen J; Nowakowska D; Niwińska A; Czapczak D; Kluska A; Piatkowska M; Wiśniewska A; Paszko Z
    Int J Cancer; 2006 Jul; 119(2):472-5. PubMed ID: 16770759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline 657del5 mutation in the NBS1 gene in breast cancer patients.
    Górski B; Debniak T; Masojć B; Mierzejewski M; Medrek K; Cybulski C; Jakubowska A; Kurzawski G; Chosia M; Scott R; Lubiński J
    Int J Cancer; 2003 Sep; 106(3):379-81. PubMed ID: 12845677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
    Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
    Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
    Roberts NJ; Grant RC; Gallinger S; Klein AP;
    Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
    Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heterozygous carriers of Slavic mutation 657del5 of NBN gene in patients with colorectal cancer].
    Seemanová E; Hoch J; Seeman P
    Cas Lek Cesk; 2011; 150(2):97-9. PubMed ID: 21560448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.